Change search
ReferencesLink to record
Permanent link

Direct link
Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: a Nested Case-Control Study
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences, Urology and Andrology.
New York, NY, USA.
New York, NY, USA.
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology.
Show others and affiliations
2015 (English)In: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 68, no 2, 207-213 p.Article in journal (Refereed) Published
Abstract [en]

Background: A disadvantage of prostate-specific antigen (PSA) for the early detection of prostate cancer (PCa) is that many men must be screened, biopsied, and diagnosed to prevent one death. Objective: To increase the specificity of screening for lethal PCa at an early stage. Design, setting, and participants: We conducted a case-control study nested within a population-based cohort. PSA and three additional kallikreins were measured in cryopreserved blood from a population-based cohort in Vasterbotten, Sweden. Of 40 379 men providing blood at ages 40, 50, and 60 yr from 1986 to 2009, 12 542 men were followed for > 15 yr. From this cohort, the Swedish Cancer Registry identified 1423 incident PCa cases, 235 with distant metastasis. Outcome measurements and statistical analysis: Risk of distant metastasis for different PSA levels and a prespecified statistical model based on the four kallikrein markers. Results and limitations: Mostmetastatic cases occurred in men with PSA in the top quartile at age 50 yr (69%) or 60 yr (74%), whereas 20-yr risk of metastasis for men with PSA below median was low (<= 0.6%). Among men with PSA > 2 ng/ml, a prespecified model based on four kallikrein markers significantly enhanced the prediction of metastasis compared with PSA alone. About half of all men with PSA > 2 ng/ml were defined as low risk by this model and had a <= 1% 15-yr risk of metastasis. Conclusions: Screening at ages 50-60 yr should focus on men with PSA in the top quartile. A marker panel can aid biopsy decision making. Patient summary: For men in their fifties, screening should focus on those in the top 10% to 25% of PSA values because the majority of subsequent cases of distant metastasis are found among these men. Testing of four kallikrein markers in men with an elevated PSA could aid biopsy decision making.

Place, publisher, year, edition, pages
Elsevier, 2015. Vol. 68, no 2, 207-213 p.
Keyword [en]
Prostate cancer, Cancer metastasis, Prostate-specific antigen, Kallikrein-related peptidases, Prostate opsy
National Category
Cancer and Oncology
URN: urn:nbn:se:umu:diva-109383DOI: 10.1016/j.eururo.2015.01.009ISI: 000360571400017PubMedID: 25682340OAI: diva2:856857
Available from: 2015-09-25 Created: 2015-09-25 Last updated: 2016-03-07Bibliographically approved

Open Access in DiVA

fulltext(4083 kB)72 downloads
File information
File name FULLTEXT01.pdfFile size 4083 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Stattin, PärJohansson, RobertJohansson, MattiasHallmans, Göran
By organisation
Urology and AndrologyOncologyNutritional ResearchDepartment of Biobank Research
In the same journal
European Urology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 72 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 53 hits
ReferencesLink to record
Permanent link

Direct link